Last reviewed · How we verify
Cessation of somatostatin analogues — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Cessation of somatostatin analogues (Cessation of somatostatin analogues) — Australasian Gastro-Intestinal Trials Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cessation of somatostatin analogues TARGET | Cessation of somatostatin analogues | Australasian Gastro-Intestinal Trials Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cessation of somatostatin analogues CI watch — RSS
- Cessation of somatostatin analogues CI watch — Atom
- Cessation of somatostatin analogues CI watch — JSON
- Cessation of somatostatin analogues alone — RSS
Cite this brief
Drug Landscape (2026). Cessation of somatostatin analogues — Competitive Intelligence Brief. https://druglandscape.com/ci/cessation-of-somatostatin-analogues. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab